Upsher-Smith has strengthened its US generics portfolio with three new launches that will compete in a combined market worth nearly $102.5m.

Amgen has filed a US patent-infringement lawsuit against Pfizer’s Hospira over its biosimilar pegfilgrastim rival to Neulasta.

Sawai’s sales increased on the back of a good performance from recently-launched products in the first nine months of its financial year. However, given the competitive environment the Japanese company is continuing to stick to its full-year forecasts.

Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.

An AAM-sponsored study by researcher Avalere Health has concluded that Medicare Part D policy changes have led to generics being placed on non-generic tiers 53% of the time in 2020, with generics placed on the ‘preferred generic’ Tier 1 just 10% of the time.

Reporting its fourth-quarter and full-year 2019 results, Sanofi saw an overall drop in generics sales following 2018’s divestment of Zentiva in Europe but enjoyed consistent turnover in emerging markets. Moreover, fourth-quarter generics turnover showed a stabilization of the business once the Zentiva comparison is removed.